VKTX241025P56000
- 0.15
- -0.03-16.67%
Viking Therapeutics Newsroom
Oppenheimer Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $138
Truist Financial Maintains Viking Therapeutics(VKTX.US) With Buy Rating
Maxim Group Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $120
Truist Financial Maintains Viking Therapeutics(VKTX.US) With Buy Rating
A Quick Look at Today's Ratings for Viking Therapeutics(VKTX.US), With a Forecast Between $90 to $125
Analysts' Opinions Are Mixed on These Healthcare Stocks: Sanofi (OtherSNYNF) and Viking Therapeutics (VKTX)
Buy Rating Affirmed for Viking Therapeutics on Promising VK0214 and VK2735 Clinical Data
Viking Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Viking Therapeutics, Maintains $90 Price Target
Oppenheimer Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $138
Oppenheimer Sticks to Their Buy Rating for Viking Therapeutics (VKTX)
Morgan Stanley Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $105
Viking Therapeutics Analyst Ratings
Oppenheimer Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $138
Stifel Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $95
Truist Financial Maintains Viking Therapeutics(VKTX.US) With Buy Rating
Truist Financial Sticks to Their Buy Rating for Viking Therapeutics (VKTX)
BTIG Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $125
Morgan Stanley Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $105
Morgan Stanley Reiterates Overweight on Viking Therapeutics, Maintains $105 Price Target